To determine the efficacy of Metformin plus SGLT2 inhibitors in type 2 obese diabetic patients attending OPD at Liaquat University Hospital Hyderabad / Jamshoro.

This quasi-experimental study was undertaken in the out-patient department of Liaquat University Hospital Hyderabad / Jamshoro from June 10th, 2022 to February 10th, 2023. All patients with type 2 DM for at least 8 months duration, already taking metformin with BMI ≥30kg/m2 and age limit from 30-55 years, of either gender were consecutively enrolled. SGLT2 inhibitors 10 mg once daily was added to Tab Metformin 500mg. The reduction in HbA1c of at least ≥0.5% from the baseline, at 6 months was considered as efficacy.

Of 114 patients, the mean age was 45.24 ±4.89 years. There were 76 (66.7%) males and 38 (33.3%) females. The mean weight, height, and BMI of the patients were 87.51 ±9.33 kg, 1.54 ±0.06 m, and 32.04 ±2.64 kg/m2 respectively. The mean pre and post HbA1c level were 9.78 ±1.43 and 8.73 ±1.39 respectively. 70 patients (61.4%) have shown reduction of HbA1c from 0.5 to 1.5% in 6 months, p-value was 0.002 significant in those with high A1c. Weight reduction was significant in both groups, BMI 30, p value was 0.02.

The efficacy of Metformin plus SGLT2 inhibitors was found in more than half of the type 2 obese diabetic patients attending OPD at Liaquat University Hospital Hyderabad / Jamshoro